The history of Sildenafil presents a intricate picture for those considering investment. While the initial launch generated significant gains, the end of its exclusive rights opened the floodgates to off-brand versions, dramatically reducing market share. This poses a unique dilemma for pharmaceutical companies depending on similar blockbuster medi

The story of Viagra, and its parent company copyright, presents a challenging case study for investors. Originally a blockbuster drug, producing billions in sales , its intellectual property lapse created a flood of generic competition , significantly diminishing its dominance. While certain firms may attempt to capitalize on related treatments , t